ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EYPT EyePoint Pharmaceuticals Inc

11.00
0.25 (2.33%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,109,590
Bid Price 10.50
Ask Price 11.00
News -
Day High 10.89

Low
5.67

52 Week Range

High
30.99

Day Low 10.41
Company Name Stock Ticker Symbol Market Type
EyePoint Pharmaceuticals Inc EYPT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.25 2.33% 11.00 17:19:57
Open Price Low Price High Price Close Price Prev Close
10.86 10.41 10.89 10.71 10.75
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
11,637 1,109,590 $ 10.76 $ 11,937,408 - 5.67 - 30.99
Last Trade Time Type Quantity Stock Price Currency
17:19:57 formt 400 $ 11.00 USD

EyePoint Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
533.19M 49.83M - 46.02M -70.8M -1.42 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

EyePoint Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No EYPT Message Board. Create One! See More Posts on EYPT Message Board See More Message Board Posts

Historical EYPT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.1111.4210.4110.99859,049-0.11-0.99%
1 Month20.2521.25510.4111.911,550,460-9.25-45.68%
3 Months25.0226.059910.4116.391,141,630-14.02-56.04%
6 Months6.3530.996.0119.871,428,1594.6573.23%
1 Year5.8330.995.6716.88984,4205.1788.68%
3 Years9.8830.992.1914.01554,4861.1211.34%
5 Years1.5930.990.35117.82666,7759.41591.82%

EyePoint Pharmaceuticals Description

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.